JPRN-UMIN000006436已完成未知
Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer - Continuous administration trial of Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancernresectable Advanced and Recurrent Pancreatic cancerJPRN-UMIN000009085OncoTherapy Science, Inc.2
已完成
2 期
Continuous administration trial of phase II study of BSC-1 in patients with ATAdult T-cell leukemia/lymphomaJPRN-jRCT2080224825Minophagen Pharmaceutical Co., Ltd.10
已完成
2 期
A phase IIb randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients BLING IISevere Sepsis in the Intensive Care patientInfection - Studies of infection and infectious agentsBlood - Other blood disordersACTRN12612000138886HMRC442
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
进行中（未招募）
不适用
Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours(TET) or Histiocitosi X (LCH) with Imatinib Mesylate. - TETIMAXPatients affected by TET or LCHEUCTR2007-006119-22-ITIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II